The FDA-approved dosing regimen is specifically designed to allow gradual physiologic adaptation, and adherence to this schedule typically results in shorter symptom duration
The appetite suppression is powerful
These drugs significantly delay gastric emptying, which can persist even after stopping the medication
These symptoms typically resolve after days to a few weeks
Researchers use this compound to study energy expenditure changes and nutrient processing pathways within animal models
Key tips for underwriting applicants with GLP1 use Immediately look for: Evidence of the underlying diagnosis (as seen in medical claims, EHR, APS) Whether the GLP-1 is FDA-approved or off-label for that condition Signs of medication adherence (12 months, regular fills) Get cautious when: A GLP1 appears without any supporting clinical context Fills are intermittent or recently initiated Theres no alignment between the medication and expected companion therapies (e.g., no CPAP with sleep apnea) Be confident when: The diagnosis is clear The drug is first line and clinically appropriate Use has been stable long enough to confer benefit Kyle Schimek, PharmD Kyle Schimek is a board-certified pharmacist and Clinical Services Manager at Milliman IntelliScript
